HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kenneth A Jamerson Selected Research

Isolated Systolic Hypertension

1/2021Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.
1/2018Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
2/2015Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
4/2012Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
3/2012Renal outcomes in hypertensive Black patients at high cardiovascular risk.
2/2011Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control.
1/2008Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
1/2008Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.
9/2004Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
7/2003The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kenneth A Jamerson Research Topics

Disease

19Hypertension (High Blood Pressure)
01/2022 - 07/2003
10Isolated Systolic Hypertension
01/2021 - 07/2003
4Chronic Kidney Failure (Chronic Renal Failure)
11/2012 - 02/2009
4Kidney Diseases (Kidney Disease)
03/2012 - 11/2003
3Proteinuria
04/2012 - 01/2008
3Cardiovascular Diseases (Cardiovascular Disease)
11/2010 - 06/2004
2Myocardial Infarction
01/2021 - 01/2018
2Stroke (Strokes)
01/2021 - 01/2018
2Cardiac Sudden Death (Sudden Cardiac Arrest)
01/2021 - 01/2018
1Diabetes Mellitus
01/2019
1Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
04/2012
1Type 2 Diabetes Mellitus (MODY)
10/2011
1Metabolic Syndrome (Dysmetabolic Syndrome X)
10/2011
1Chronic Renal Insufficiency
09/2010
1Edema (Dropsy)
09/2005
1Renal Insufficiency (Renal Failure)
11/2003
1Hypertensive Nephropathy
11/2003

Drug/Important Bio-Agent (IBA)

10Antihypertensive Agents (Antihypertensives)IBA
01/2021 - 07/2003
9Amlodipine (Norvasc)FDA LinkGeneric
01/2021 - 06/2004
7Hydrochlorothiazide (Esidrix)FDA LinkGeneric
01/2021 - 09/2004
7benazepril (Briem)FDA LinkGeneric
01/2021 - 06/2004
6Proliferating Cell Nuclear Antigen (PCNA)IBA
10/2018 - 01/2018
3ThiazidesIBA
01/2022 - 01/2008
3CreatinineIBA
11/2012 - 09/2010
3Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2008 - 11/2003
3Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2008 - 11/2003
2DiureticsIBA
01/2022 - 01/2008
2Pharmaceutical PreparationsIBA
01/2018 - 09/2004
1Calcium Channels (Calcium Channel)IBA
01/2021
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/2021
1Hypoglycemic Agents (Hypoglycemics)IBA
01/2019
1Insulin (Novolin)FDA Link
04/2012
1Telmisartan (Micardis)FDA Link
10/2011
1Proteins (Proteins, Gene)FDA Link
09/2010
1N,N-dimethylarginine (asymmetric dimethylarginine)IBA
02/2009
1Nitric Oxide Synthase (NO Synthase)IBA
02/2009
1dimethylarginineIBA
02/2009
1Valsartan (Vals)FDA Link
09/2005
1Biomarkers (Surrogate Marker)IBA
06/2004

Therapy/Procedure

11Therapeutics
01/2022 - 07/2003
2Resuscitation
01/2021 - 01/2018
1Secondary Prevention
11/2010
1Diet Therapy (Therapy, Diet)
05/2009